Akero Therapeutics (AKRO) said Monday that a phase 2b study of its lead product candidate efruxifermin showed a "statistically significant" reversal of compensated cirrhosis caused by metabolic dysfunction-associated steatohepatitis, or MASH.
The company said that among patients with baseline and week 96 biopsies, 39% of those treated with efruxifermin showed reversal of cirrhosis without worsening MASH, compared with 15% for the placebo group. In the intent-to-treat group, 29% of patients treated achieved reversal, compared with about 12% for placebo, the company added.
Efruxifermin was well-tolerated, with no deaths in the treatment groups and most side effects being mild, transient, and gastrointestinal in nature, according to Akero.
The company said it is advancing its evaluation of efruxifermin in an ongoing phase 3 trial.
The company's shares soared past 115% in recent Monday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.